Skip to content

The Effects of Blood Pressure Reduction on Cerebral Perfusion and Cognition in the Elderly Population

Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00966199
Acronym
MBRACE
Enrollment
60
Registered
2009-08-26
Start date
2009-09-30
Completion date
2013-12-31
Last updated
2009-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

blood pressure, aging, cerebrovascular circulation, hypertension

Brief summary

The purpose of this study is to determine if a reduction in systolic blood pressure induced by anti-hypertensive medication results in changes in cerebral perfusion and cognition in hypertensive elderly. Hypertensive elderly will be treated using open-label anti-hypertensive medication for 8-12 weeks. Changes in cerebral perfusion and cognition will be assessed before and after treatment.

Interventions

8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication

Sponsors

Dutch Heart Foundation
CollaboratorOTHER
Radboud University Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \>= 70 years * Systolic office blood pressure \>= 160 mmHg * Systolic home blood pressure \>= 155 mmHg

Exclusion criteria

* Diabetes Mellitus * Atrial fibrillation * Dementia * Renal failure requiring dialysis * Life expectancy of less than 1 year * Disabling stroke * Contraindication for MRI or anti-hypertensive medication * Systolic blood pressure \> 220 mmHg

Design outcomes

Primary

MeasureTime frame
Cerebral blood flowT1, 8-12 weeks of treatment, T2

Secondary

MeasureTime frame
Cognitive functioning assessed by neuropsychological testingT1, 8-12 weeks of treatment, T2-3

Countries

Netherlands

Contacts

Primary ContactJaap C Sijbesma, MD
J.Sijbesma@ger.umcn.nl0243616772

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026